StAR related lipid transfer domain containing 8Genealiases: ARHGAP38 · DLC3 · STARTGAP3
Q-omics provides the consensus-scored STARD8 profile across patient tissues and cancer cell-line models. STARD8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STARD8 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, STARD8 RNA expression shows 23,560 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where STARD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STARD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STARD8 survival associations across molecular data types. STARD8 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STARD8 RNA expression–survival associations across cancer types. High STARD8 expression shows unfavorable associations in STAD, BLCA, LUSC and LAML, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STARD8 RNA expression.
This table summarizes STARD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STARD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STARD8 shows lower tumor expression in BLCA, KICH, LUAD, THCA, LUSC and KIRP. The BLCA box plot shows higher STARD8 RNA expression in normal versus tumor tissue (log2 FC = −1.422, t-test p < 0.001).
This table shows molecular features associated with STARD8 in patient tissues and cancer cell lines. In patient samples, STARD8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STARD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
